MitrAssist Overview
MitrAssist has developed an approach to treating patients with life-threatening mitral regurgitation (MR) that involves neither repair nor replacement. Instead, the companys proprietary valve implant is placed on top of the natural valve to work in unison with it and to enhance valve functionality. MitrAssists valve-in-valve approach overcomes the various challenges of MR and offers an alternative treatment solution for all MR patients. Made from biomedical and biological materials, MitrAssists valve offers improved biocompatibility and patient recovery time.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Centurium, 6 Dimensions lead $100m Series C round for medtech startup MitrAssist
MitrAssist, an Israel-based medical devices developer, has raised nearly $100 million in a Series C funding round to accelerate the R&D and commercialisation of its cardiovascular technologies. The round was led by existing shareholders Centurium Capital and 6 Dimensions Capital. Other participants included state capital investors from the Jiading District of Shanghai and Haiheng Investment, as well as Hefei Industry Investment Group and other domestic investors. MitrAssist, which is expanding in China, develops a minimally invasive mitral valve implant to enhance the valves functionality and prevent the need for complete valve replacement.
InvestmentExpand
growth-positive
Shanghai MITRASSIST Medical Closes Nearly $100 Million Series C Financing - G-MedTech News Center
Shanghai-based MITRASSIST Medical has raised nearly $100 million in a Series C financing round led by Centurium Capital and 6 Dimensions Capital, with participation from several other investors. The funds will be used for the development and commercialization of mitral valve replacement products and aortic polymer valve products. The company, which specializes in innovative cardiovascular medical devices, recently signed an agreement to invest $270 million in Hefei City, Anhui Province, to establish a research and development, production and commercialisation base for cardiovascular products and high-value consumables.
InvestmentExpand
growth-positive
Israeli medical valve co MitrAssist raises $50m
Israeli medical device company MitrAssist has raised $50 million in a funding round, bringing the total amount raised by the company to $85 million. The funding round included current investors Chinese Fosun Pharma and insurance company Ping-An, as well as four large Chinese funds. MitrAssist, which has developed a medical valve for symptomatic patients with primary or secondary mitral regurgitation, plans to use the funding to complete clinical trials and reach the Chinese market by 2024. The company also plans to hire more employees in early 2021 to develop more ideas in the field of structural heart diseases.
InvestmentExpand
growth-positive
Heart Valve Company MitrAssist Raises $30M
Israeli biotech company MitrAssist has raised $30 million in a funding round led by Fosun Pharma and Ping An Insurance Company. The company, which developed a heart valve implant that can be installed through a thigh catheterization, received $16 million based on its pre-closing valuation of $80 million. It will receive an additional $14 million when it begins clinical trials within a year, based on a pre-closing valuation of $136 million. MitrAssist was founded in 2009 by Gil Naor.
Investment
growth-positive
Fosun Leads $30 Million Round for Heart Valve Company MitrAssist
MitrAssist Ltd, an Israel-based biotech company, has raised $30 million in an investment round led by Fosun Pharma and participated by Ping An Insurance Company of China. The company has developed a valve implant that can be installed through thigh catheterization, providing a less invasive alternative to heart surgery. MitrAssist aims to treat mitral regurgitation, a prevalent heart valve disease in the US. The investment will be used for clinical trials, with $16 million received initially and an additional $14 million expected when the trials begin. MitrAssist plans to market its valve in Europe first and is already in contact with regulatory authorities and doctors in Germany and New York.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $204M |
| Last funding | $100M |
| Stage | C |
| Rounds | 5 |
| Investors | 7 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | mitrassist.com |
Locations
Alon Hatavor 20, Caesarea, Israel
Photos & Videos
No files yet
